Low-dose Radiation Plus Orelabrutinib for Early-stage MALT Lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests combining very low-dose radiation therapy with a targeted drug called orelabrutinib (a type of cancer-fighting protein inhibitor) as a first treatment for early-stage MALT lymphoma, a slow-growing blood cancer. The goal is to see if this combination can shrink or control the cancer with fewer side effects than standard chemotherapy.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older and have been diagnosed with MALT lymphoma (a type of lymphoma affecting tissues outside lymph nodes)
- Your lymphoma has at least one measurable tumor outside the spleen that is larger than 1 cm
- You have never received chemotherapy, targeted therapy, or other systemic cancer treatments for this diagnosis
- You have an ECOG performance status of 0–1 (able to do light activity; if bedridden more than 50% of the day, you don't qualify)
- Your blood counts and organ function (liver, kidney, heart) are within safe ranges for this treatment
- You are willing to use contraception if you could become pregnant, and you are not currently pregnant or breastfeeding
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of low-dose radiation and an oral targeted therapy (orelabrutinib) for patients with a slow-growing type of lymphoma called MALT lymphoma. The goal is to see if this approach can effectively treat the disease while reducing side effects.
This trial tests a combination of two targeted drugs, orelabrutinib and rituximab, as the first systemic treatment for marginal zone lymphoma. If you have not yet had chemotherapy for your lymphoma and meet certain health criteria, you may be able to join.
This trial tests a combination of a targeted drug (Orelabrutinib) and radiation therapy for adults newly diagnosed with a slow-growing lymphoma around the eye. The goal is to see if this approach works well and is safe for people who have not had treatment before.
This trial tests a combination of targeted therapy (orelabrutinib) plus chemotherapy (BR) or antibody therapy (G) for people with untreated marginal zone lymphoma. It aims to see if this combination can help patients who haven't had treatment yet.
This trial tests a combination of targeted drugs for people with a type of lymphoma called marginal zone lymphoma (MZL) that has not been treated before. The drugs attack cancer cells in different ways, and the treatment plan may adjust based on how you respond.
This trial tests a targeted drug called orelabrutinib for people with a specific type of stomach lymphoma that is linked to an active H. pylori infection. The goal is to see if the drug can help shrink or control the lymphoma.
Hear when a new MALT Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.